EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease



Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease



Infection and Immunity 32(2): 534-541



The results of the present investigation indicate a simple approach to the development of a single-vaccine formula which may ultimately be used to confer protection against both cholera and certain types of Escherichia coli diarrheal disease in humans and domestic animals. The design of the vaccine is based on the well-documented ability of cholera antitoxin to neutralize both cholera and heat-labile E. coli enterotoxins (CT and LT, respectively) and on the ability of killed E. coli to enhance the immune response to cholera toxoid and, possibly, to conventional cholera vaccine as well. Evidence presented shows that a parenterally administered E. coli vaccine, prepared from an LT-only enterotoxigenic strain, reproducibly elevated rabbit antitoxin responses to cholera toxoid and that such responses correlated with dramatic protection against live cholera vibrios and the homologous E. coli strain in the rabbit ligated loop model of diarrheal disease. The results show also that cholera vaccine acted to suppress the rabbits' immune response to the cholera toxoid and E. coli vaccine formula, even though all three antigens combined still provided significant protection against live organism challenge. On the basis of data presently available, the vaccine formula would be composed simply of cholera toxoid and E. coli vaccine, but may also include cholera vaccine. Since it has already been established that cholera toxoid and cholera vaccine are each safe for human use, additional vaccine development would require investigation of the safety of E. coli vaccine, alone and in combination with the other components.

(PDF 0-2 workdays service: $29.90)

Accession: 005132162

Download citation: RISBibTeXText

PMID: 7019073



Related references

Prospects for the development of a vaccine against cholera and escherichia coli diarrheal disease. Robbins, J B , J C Hill And J C Sadoff (Ed ) Seminars in Infectious Disease, Vol 4 Bacterial Vaccines; International Symposium, Sept 15-18, 1980 Xxxiv+461p Thieme-Stratton, Inc : New York, N Y , Usa; Georg Thieme Verlag: New York, N Y , Usa; Stuttgart, West Germany Illus P89-96, 1982

Experimental diarrheal disease of human volunteers due to Escherichia coli; In Epidemic and endemic diarrheal diseases of the infant. 1956

Characterization of enterotoxigenic escherichia coli etec isolated from us soldiers with diarrheal disease during operation desert shield implications for vaccine development. Gastroenterology 102(4 PART 2): A597, 1992

Experimental diarrheal disease of human volunteers due to Escherichia coli. Annals of the New York Academy of Sciences 66(1): 71-77, 1956

From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Indian Journal of Medical Research 133: 188-196, 2011

Expression of cloned cholera enterotoxin gene in Escherichia coli and possibilities of vaccine development. Lancet 1(8283): 1239-1240, 1982

Excretion of cholera toxin from Escherichia coli: a potential oral vaccine for cholera. Biochemical and Biophysical Research Communications 153(3): 967-972, 1988

The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clinical and Vaccine Immunology 19(12): 1921-1931, 2013

Studies on the development of hog cholera live vaccine 3. field application of experimental hog cholera vaccine. Research Reports of the Rural Development Administration (Suweon) 32(1 VET): 49-55, 1990

Immunization of suckling pigs against entero toxigenic escherichia coli induced diarrheal disease by vaccinating dams with purified 987 or k 99 pili protection correlates with pilus homology of vaccine and challenge. Infection and Immunity 22(3): 771-777, 1978

Construction of plasmid vectors with a non-antibiotic selection system based on the Escherichia coli thyA+ gene: application to cholera vaccine development. Gene 107(1): 139-144, 1991

Studies on the development of a Escherichia coli subunit vaccine against calf diarrhoea. I. Distribution of enterotoxigenic Escherichia coli and purification of K99 and F41 pilus antigens. II. Immunogenicity and protective efficacy of K99 and F41 pilus vaccines in experimental animals. Korean Journal of Veterinary Research 26(1): 97-102, 103-108, 1986

Construction of plasmid vectors with a non antibiotic selection system based on the escherichia coli thya positive gene application to cholera vaccine development. Gene (Amsterdam) 107(1): 139-144, 1991